当前位置： SCI文献检索 > CARDIOVASCULAR DRUGS AND THERAPY期刊下所有文献 > Quinapril hydrochloride effects on renal function in patients with renal dysfunction and hypertension: a drug-withdrawal study.

Quinapril hydrochloride effects on renal function in patients with renal dysfunction and hypertension: a drug-withdrawal study.

Abstract：

:Patients with mild to moderate hypertension (diastolic blood pressure > or = 95 and < or = 115 mmHg) and renal dysfunction entered one of two studies to assess the safety of efficacious daily doses of quinapril on renal function and blood pressure. Twenty-four patients with moderate renal impairment (MRI) (creatinine clearance > 30 and < or = 60 ml/min) entered 24 weeks of open-label quinapril treatment; 31 patients with chronic renal failure (CRF) (creatinine clearance < 30 ml/min) entered 16 weeks of open-label quinapril treatment. Patients with MRI initially received quinapril 5 mg once daily (qd) followed by titration to a maximum dosage of 40 mg/day (furosemide optional at 40 mg only). Patients with CRF initially received quinapril 2.5 mg qd and were titrated up to 20 mg/day (furosemide optional). Open-label quinapril treatment resulted in significant decreases in mean systolic (SBP) and diastolic (DBP) blood pressure. The 20 patients with MRI and the 28 with CRF who completed the open-label phase were then randomly assigned to continue active drug or to receive placebo in a 4-week, double-blind, drug-withdrawal phase. During the double-blind withdrawal phase, placebo-treated patients had significant increases in mean SBP and DBP from the end of open label. Creatinine clearance was essentially unchanged following open-label quinapril treatment or quinapril withdrawal. In conclusion, in patients with mild to moderate hypertension and renal dysfunction, quinapril in dosages of 5-40 mg qd for patients with MRI and 2.5 to 20 mg qd for patients with CRF significantly reduces blood pressure without adversely affecting renal function.

journal_name

Cardiovasc Drugs Ther

journal_title

Cardiovascular drugs and therapy

authors

Miller MA,Texter M,Gmerek A,Robbins J,Shurzinske L,Canter D

doi

10.1007/BF00877336

subject

Has Abstract

pub_date

1994-04-01 00:00:00

pages

271-5

issue

2

eissn

0920-3206

issn

1573-7241

journal_volume

8

pub_type

临床试验,杂志文章,多中心研究,随机对照试验

相关文献

CARDIOVASCULAR DRUGS AND THERAPY文献大全
  • Aleglitazar, a Balanced Dual PPARα and -γ Agonist, Protects the Heart Against Ischemia-Reperfusion Injury.

    abstract：PURPOSE:To evaluate whether aleglitazar (Ale), a dual PPARα/γ agonist, has additive effects on myocardial protection against ischemia-reperfusion injury. METHODS:Human cardiomyocytes (HCMs), cardiomyocytes from cardiac-specific PPARγ knockout (MCM-PPARγ (CKO) ) or wild type (MCM-WT) mice were incubated with different ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-016-6650-9

    authors： Qian J,Chen H,Birnbaum Y,Nanhwan MK,Bajaj M,Ye Y

    更新日期：2016-04-01 00:00:00

  • Inhibitory effect of clentiazem (TA-3090), a new calcium antagonist, on balloon catheter-induced intimal thickening of rabbit aorta.

    abstract：:Male Japanese white rabbits were fed a restricted amount (100 g/head/day) of an atherogenic diet containing 0.2% cholesterol and 6% peanut oil during an 8-week experimental period. Atherosclerotic lesions, characterized by intimal thickening with lipid deposition, were produced by de-endothelialization of the rabbit a...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF00878516

    authors： Saso Y,Ohtani A,Odawara A,Iwasaki H,Takashima K,Morita T

    更新日期：1993-04-01 00:00:00

  • Functional antagonism of different angiotensin II type I receptor blockers in human arteries.

    abstract：OBJECTIVES:To evaluate and compare the functional type and the degree of antagonism of the selective angiotensin II type 1 receptor blockers (ARB) losartan, EXP 3174 (the active metabolite of losartan), valsartan and candesartan in human internal mammary arteries. METHODS:Human internal mammary arteries were obtained ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1023/a:1021729909456

    authors： Wagenaar LJ,Voors AA,Buikema H,van Buiten A,Lübeck RH,Boonstra PW,van Veldhuisen DJ,van Gilst WH

    更新日期：2002-07-01 00:00:00

  • Verapamil and diet halt progression of atherosclerosis in cholesterol fed rabbits.

    abstract：:The present study was designed to evaluate the effects of oral verapamil and normal diet on regression of atherosclerotic plaque in cholesterol fed rabbits. Forty-three rabbits were separated into 6 groups and studied for 24 weeks. All groups had a cholesterol diet for the first 12 weeks. Group I was then sacrificed a...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF02125835

    authors： Sievers RE,Rashid T,Garrett J,Blumlein S,Parmley WW

    更新日期：1987-01-01 00:00:00

  • Myocardial ischemia and reperfusion: the role of oxygen radicals in tissue injury.

    abstract：:Thrombolytic therapy has gained widespread acceptance as a means of treating coronary artery thrombosis in patients with acute myocardial infarction. Although experimental data have demonstrated that timely reperfusion limits the extent of infarction caused by regional ischemia, there is growing evidence that reperfus...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/BF00133206

    authors： Werns SW,Lucchesi BR

    更新日期：1989-01-01 00:00:00

  • Fish oil and the prevention and regression of atherosclerosis.

    abstract：:Epidemiological studies in the seventies have put forward that dietary rather than genetic factors are responsible for the lower incidence of ischemic heart disease in Greenland Inuit and have generated a large body of both in vitro and in vivo experimental studies, exploring the putative favorable effects of fish (oi...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/BF00877326

    authors： Sassen LM,Lamers JM,Verdouw PD

    更新日期：1994-04-01 00:00:00

  • Glucose-insulin-potassium (GIK) for acute myocardial infarction: a negative study with a positive value.

    abstract：:Glucose-insulin-therapy for acute myocardial infarction (AMI) has had a long history, going back 37 years to the pioneering concepts of Sodi-Pallares. Although a recent meta-analysis of a number of smaller trials has suggested mortality benefit, it is only the South American trial, published in Circulation in 1998, th...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 评论,社论,评审

    doi：10.1023/a:1007757407246

    authors： Apstein CS,Opie LH

    更新日期：1999-05-01 00:00:00

  • Lisinopril in the treatment of congestive heart failure in elderly patients: comparison versus captopril.

    abstract：:The present study was performed in order to compare the efficacy, safety, and tolerability of lisinopril, a long-acting angiotensin-converting enzyme (ACE) inhibitor, with captopril, the shorter acting ACE inhibitor available, in the treatment of elderly patients (mean age 70 +/- 0.5 years) with congestive heart failu...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1023/a:1007704024393

    authors： Morisco C,Condorelli M,Crepaldi G,Rizzon P,Zardini P,Villa G,Argenziano L,Trimarco B

    更新日期：1997-03-01 00:00:00

  • Use of combined chemotherapy with etoposide and methotrexate, both associated to lipid nanoemulsions for atherosclerosis treatment in cholesterol-fed rabbits.

    abstract：PURPOSE:Treatment of atherosclerotic rabbits with intravenous methotrexate or etoposide carried in lipid nanoemulsions (LDE) markedly reduced the lesions in the aorta. Here, the combined treatment with LDE-methotrexate and LDE-etoposide was investigated aiming to increase the anti-atherosclerosis effect. METHODS:Thirt...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-014-6566-1

    authors： Leite AC Jr,Solano TV,Tavares ER,Maranhão RC

    更新日期：2015-02-01 00:00:00

  • Should calcium antagonists be first-line agents in the treatment of cardiovascular disease? The public health perspective.

    abstract：:The calcium antagonist (CA) controversy has been fueled in part by disagreements among scientists and clinicians over the scientific documentation required for drugs used to treat lifelong conditions. From a public health perspective, there are three unanswered questions: (1) Does long-term use of CAs convey health be...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF00051111

    authors： Furberg CD,Psaty BM

    更新日期：1996-09-01 00:00:00

  • Central and peripheral irisin differentially regulate blood pressure.

    abstract：INTRODUCTION:Irisin is a newly identified 112 amino acid hormone, derived as a product of fibronectin type III domain containing 5 (FNDC5), which is highly related to metabolic activity in skeletal muscle and brown fat. The effects of irisin on cardiovascular functions are unknown. PURPOSE:To explore the effects of ce...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-015-6580-y

    authors： Zhang W,Chang L,Zhang C,Zhang R,Li Z,Chai B,Li J,Chen E,Mulholland M

    更新日期：2015-04-01 00:00:00

  • Comparison of captopril with enalapril in the treatment of heart failure: influence on hemodynamics and measures of renal function.

    abstract：:Twenty-nine patients with severe heart failure (NYHA III) were randomly assigned to receive therapy with an angiotensin converting enzyme inhibitor (ACE inhibitor), either captopril or enalapril. The mean daily dosage of captopril was 56 +/- 5 mg and of enalapril 9.5 +/- 0.4 mg. After a mean of 8 +/- 1 days, the influ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF00054567

    authors： Osterziel KJ,Dietz R,Harder K,Kübler W

    更新日期：1992-04-01 00:00:00

  • Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

    abstract：:A survey of the pharmacokinetic properties of the three prototypical calcium antagonist agents shows that they have in common a very high rate of hepatic first-pass metabolism with, in the case of verapamil and diltiazem, the formation of an active metabolite that affects the dose during chronic therapy. Therefore, th...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/BF01865507

    authors： Opie LH

    更新日期：1989-08-01 00:00:00

  • Infarct size as estimated from peak creatine kinase and lactate dehydrogenase is probably reduced in patients using calcium antagonists at the onset of symptoms.

    abstract：:In animal models, calcium antagonists (Ca-A) administered before ischemia and reperfusion reduced myocardial necrosis, attenuated postischemic contractile dysfunction, and reduced tissue calcium. In 753 patients with acute myocardial infarction (AMI), we examined if use of Ca-A at the onset of symptoms (n = 127 patien...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1023/a:1007727518684

    authors： Landmark K,Abdelnoor M,Kilhovd B,Dørum HP

    更新日期：1997-09-01 00:00:00

  • Quality of life on treatment with metoprolol in dilated cardiomyopathy: results from the MDC trial. Metoprolol in Dilated Cardiomyopathy trial.

    abstract：:Quality of life in heart failure patients is receiving increased attention as a reflection of a treatment's potential secondary benefit of general well-being and daily functioning. The Metoprolol in Dilated Cardiomyopathy (MDC) trial was conducted as a large, multicenter trial to establish the effects of metoprolol on...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1007/BF02627961

    authors： Wiklund I,Waagstein F,Swedberg K,Hjalmarsson A

    更新日期：1996-07-01 00:00:00

  • Effects of almokalant, a class III antiarrhythmic agent, on supraventricular, reentrant tachycardias. Almokalant Paroxysmal Supraventricular Tachycardia Study Group.

    abstract：:The aim of the present study was to investigate the effects of almokalant on sustained reentrant supraventricular tachycardias. Reentrant tachycardias were induced, using transesophageal atrial stimulation, in 82 patients with atrioventricular reentrant tachycardia (n = 54) or AV nodal reentrant tachycardia (n = 28). ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1007761825414

    authors： Darpö B,Edvardsson N

    更新日期：1997-07-01 00:00:00

  • Effects of calcium channel agonism by Bay-K-8644 on ventricular fibrillation threshold of isolated heart.

    abstract：:The hypothesis tested was that enhanced entry of calcium into cardiac cells would increase the susceptibility to ventricular fibrillation as measured by the ventricular fibrillation threshold (VFT) of the isolated perfused rat heart. Bay-K-8644 was used as a calcium-channel agonist. There was a biphasic effect with a ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF00052561

    authors： Worthington MG,Opie LH

    更新日期：1992-12-01 00:00:00

  • Cholesterol confusion in primary prevention of coronary artery disease.

    abstract：:Despite the impressive relation between an increased blood cholesterol and increased mortality from coronary artery disease and despite the persuasive results of cholesterol-lowering trials in secondary prevention, there are increasing reservations about the wisdom of lowering moderately raised blood cholesterol level...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 社论

    doi：10.1007/BF00878930

    authors： Opie LH

    更新日期：1993-11-01 00:00:00

  • Vascular complications in hypertension: the VHAS study. Verapamil-Hypertension Atherosclerosis Study.

    abstract：:The VHAS (Verapamil-Hypertension Atherosclerosis Study) Investigators entered 1464 patients with essential hypertension and blood pressure (BP) values > or = 160 mmHg systolic and 95 mmHg diastolic (DBP) but excluded those with a DBP > or = 115 mmHg, and those with diabetes mellitus or previous myocardial infarction o...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1007/BF00877865

    authors： Zanchetti A

    更新日期：1995-08-01 00:00:00

  • Cytotoxicity of amiodarone in cultured human endothelial cells.

    abstract：:As damage to the pulmonary vascular endothelium may be responsible for the lung toxicity of amiodarone, we evaluated the cytolytic toxicity of the drug in cultures of endothelial cells. Cells were cultured from human umbilical cord veins. Amiodarone caused a vacuolization of the cells with liberation of both lactate d...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF00050996

    authors： Baudin B,Bénéteau-Burnat B,Giboudeau J

    更新日期：1996-11-01 00:00:00

  • Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population.

    abstract：PURPOSE:A multicentre, randomized, double-blind, placebo-controlled, parallel-group study aimed to define the potential positive effect of dipeptidyl peptidase-4 inhibition on left ventricular systolic function (LVSF) beyond glycemic control in type 2 diabetes mellitus (T2DM) (DYDA 2™ trial). METHODS:Individuals with ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-019-06898-6

    authors： Giorda CB,Cioffi G,Lucci D,Nada E,Ognibeni F,Mancusi C,Latini R,Maggioni AP,DYDA 2 Investigators.

    更新日期：2019-10-01 00:00:00

  • Roles of hepatocyte growth factor and mast cells in thrombosis and angiogenesis.

    abstract：:Concentrations of the circulating hepatocyte growth factor (HGF) increase in the very early phase of acute myocardial infarction, and are a marker of arterial thrombosis. A recently developed, highly sensitive HGF assay can detect the early stages of arterial thrombosis in patients with unstable angina pectoris, acute...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1023/B:CARD.0000041252.33870.74

    authors： Matsumori A

    更新日期：2004-07-01 00:00:00

  • Randomized, controlled trial of antioxidant vitamins and cardioprotective diet on hyperlipidemia, oxidative stress, and development of experimental atherosclerosis: the diet and antioxidant trial on atherosclerosis (DATA).

    abstract：:The effects of administration of guava and papaya fruit (100 g/day), vegetables, and mustard oil (5 g/day) (group A); antioxidant vitamins C (50 mg/day) and E (30 mg/day), plus betacarotene (10 mg/day) (group B); a high-fat (5-10 g/day) (group C); or a low-fat (4-5 g/day) diet (group D) were compared over 24 diet week...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF00879869

    authors： Singh RB,Niaz AM,Ghosh S,Agarwal P,Ahmad S,Begum R,Onouchi Z,Kummerow FA

    更新日期：1995-12-01 00:00:00

  • Stunning of the myocardium: an update.

    abstract：:When severely ischemic myocardium is reperfused, prolonged myocardial dysfunction--a phenomenon named myocardial stunning--frequently occurs. Stunning also occurs in a variety of other situations. These include myocardium located adjacent to infarcted tissue, transient increase in myocardial O2 demands in the presence...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章,评审

    doi：10.1007/BF00053546

    authors： Braunwald E

    更新日期：1991-10-01 00:00:00

  • Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis.

    abstract：PURPOSE:Platelets are essential for primary hemostasis; however, platelet activation also plays an important proinflammatory role. Inflammation promotes the development of cardiac fibrosis and heart failure induced by hypertension. In this study, we aimed to determine whether inhibiting platelet activation using clopid...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-013-6471-z

    authors： Jia LX,Qi GM,Liu O,Li TT,Yang M,Cui W,Zhang WM,Qi YF,Du J

    更新日期：2013-12-01 00:00:00

  • Enoximone: true inotropic effects? Do they cause ischemia? Analysis of end-systolic pressure-volume relations using the conductance (volume) catheter technique.

    abstract：:True positive inotropy of enoximone is hard to prove clinically. It could increase the risk of myocardial ischemia when used in coronary artery disease (CAD). The analysis of the end-systolic pressure-volume relationship (ESPVR) as a load-independent parameter of the contractile left ventricular function (LVF) allows ...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/BF02018269

    authors： Thormann J,Hueting J,Kremer P,Wissemann J,Mitrovic V,Dieterich HA,Schlepper M

    更新日期：1990-10-01 00:00:00

  • Effects of amlodipine and isosorbide dinitrate on exercise-induced and ambulatory ischemia in patients with chronic stable angina pectoris.

    abstract：:This study was designed to compare once-daily administration of 5-10 mg amlodipine with two daily doses of 40 mg sustained-release isosorbide dinitrate in 59 patients with stable angina using a randomized, double-blind, crossover study design. Anginal episodes, nitroglycerin consumption, and possible adverse events we...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1007726722284

    authors： Steffensen R,Melchior T,Bech J,Nissen H,Haastrup B,Grande P,Rasmussen V,Hansen JF,Skagen K,Haghfelt T

    更新日期：1997-11-01 00:00:00

  • Role of ischemia in postinfarction heart failure: hypothetical considerations based on use of verapamil in the DAVIT II Study. Danish Study Group on Verapamil in Myocardial Infarction.

    abstract：:Based on a retrospective analysis of the DAVIT II database, we attempted to propose subgroups of post-infarction patients with heart failure, who might benefit or not benefit from antiischemic medical intervention. In DAVIT II, patients were randomized in a double-blind fashion to either verapamil 360 mg/day or placeb...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1007/BF00877400

    authors： Jespersen CM

    更新日期：1994-12-01 00:00:00

  • Azelnidipine inhibits H2O2-induced cell death in neonatal rat cardiomyocytes.

    abstract：PURPOSE:Oxidative stress plays an important role in the pathogenesis of cardiovascular diseases. Azelnidipine is a novel dihydropyridine calcium channel blocker. Several studies have demonstrated that some dihydropyridine calcium channel blockers have antioxidant effects. We evaluated the antioxidant effects of azelnid...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 杂志文章

    doi：10.1007/s10557-007-6008-4

    authors： Koyama Y,Takeishi Y,Takahashi H,Shishido T,Arimoto T,Niizeki T,Harada M,Suzuki S,Kitahara T,Sasaki T,Kubota I

    更新日期：2007-02-01 00:00:00

  • Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta.

    abstract：:The purpose of this study was to examine the effects of the angiotensin-converting enzyme (ACE) inhibitor cilazapril on the elastic properties of the aorta. A standard diuretic antihypertensive drug, hydrochlorothiazide, served for comparisons. Increased aortic stiffness leads to a reduction of the buffering windkesse...

    journal_title：Cardiovascular drugs and therapy

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF00051130

    authors： Breithaupt-Grögler K,Leschinger M,Belz GG,Butzer R,Erb K,de May C,Sinn W

    更新日期：1996-03-01 00:00:00